Time filter

Source Type

Aleinikova O.V.,Republican Research and Practical | Shamardinal A.V.,Regional Childrens Hospital | Boichenko E.G.,Childrens Hospital One | Dudkin S.A.,Town Childrens Hospital Four | And 16 more authors.
Terapevticheskii Arkhiv

Aim. To evaluate the efficiency of the original ALL-MB-2002 protocol within the multicenter study of treatment of acute lymphoblastic leukemia (ALL) in children. Subjects and methods. A total of 1873 primary patients with ALL aged 1 to 18 years, of whom 1544 patients were enrolled in this study, were notified at 36 clinics of Russia and Belarus from April 15, 2002, to January 1, 2008. Results. With the median observation of 4.12 years, 7-year event-free survival (EFS) was 73±13%; overall survival (OS) 78±2%; relapse-free survival 82±1%. The rates of EFS and OS were equal and amounted to 76±2 and 80±2% in the standard-risk group (SRG) and intermediate-risk group (ImRG), respectively. In the high-risk group (HRG) patients, EFS and OS were as high as 30±6 and 37±6%, respectively. The frequency of relapses with central nervous system lesion was as much as 4.7% in all the patients, 6-year cumulative risk for isolated neurorecurrences being 2.5% in the SRG patients. Adolescents, patients with the baseline leukocytosis (more than 100 • 109/l, and those with a splenic size of over 4 cm or more from the costal arch margin had substantially worse survival rates. A poor early response to therapy (on induction days 8 and 15) was also associated with its lower efficiency. Conclusion. Despite a considerable rise in the number of centers and a slight increase in the intensity of therapy, the results of the new ALL-MB-2002 protocol are as minimum equivalents obtained in the use of the previous ALL-MB-91 protocol. A significant improvement in the overall results of therapy and a reduction in the cumulative risk for isolated neurorecurrences were noted in the ImRG patients. Source

Illek Y.Y.,Kirov State Medical Academy | Zaytseva G.A.,Kirov Research Institute of Hematology and Blood Transfusion | Galanina A.V.,Kirov State Medical Academy | Vasilieva Y.A.,Kirov Children Clinical Hospital | And 2 more authors.
Sovremennye Tehnologii v Medicine

The aim of the investigation was to study the state of immunologic responsiveness, immunomodulating and anti-relapse effects of ozone therapy in children with severe extended atopic dermatitis. Materials and Methods. We examined 64 children (38 boys and 26 girls) aged 5-10 years with severe extended atopic dermatitis. Group 1 patients (n=33) received complex standard treatment, group 2 (n=31) - complex therapy in combination with ozone therapy. Results. Complex standard therapy resulted in complete, though short, clinical remission; and in remission the patients preserved the changed parameters of cellular and humoral components of immune system, nonspecific resistance and the levels of pro-inflammatory cytokines in blood serum; while the patients receiving complex therapy combined with ozone therapy were found to have more rapid improvement of clinical indices, normalization of the most parameters of immunologic responsiveness and a long clinical remission. Source

Korotayeva K.N.,Vyatka State Humanities University | Vyaznikov V.A.,Kirov Regional Clinical Hospital | Tsirkin V.I.,Kirov State Medical Academy | Kostjaev A.A.,Kirov Research Institute of Hematology and Blood Transfusion
Human Physiology

Influence of adrenaline (10-9 to 10-4 g/ml) on the contraction amplitude caused by electrostimuli (1Hz, 5 ms, 25-30 V) and inotropic and adrenomodulation activities of blood serum of nonpregnant women (at dilutions of 1: 10 000, 1 : 1000, 1 : 500, 1 : 100, 1 : 50, 1 : 10, and 1 : 5) have been studied. The study has been carried out on isolated myocardium strips of the right atrial auricle that were taken from 43 patients with ischemic illness of the heart and 9 patients with valvular heart diseases of various etiologies upon venous cannula insertion during an aortocoronary bypass. Direct dependence of the contraction amplitude on the cardiac output according to Teicholz has been found. This meant that strips of the right atrial auricle reflected the contractility of the left ventricle myocardium. Adrenaline has been shown to dose-dependently increase the amplitude of evoked contractions in the concentration interval from 10-7 to 10-6 g/ml and had no influence from 10-9 to 10-8 g/ml (dissociation constant, 2 × 10-7 g/ml), which proved a decrease in the β-adrenoreceptor's (β-AR) activation. Blood serum in a dilution range from 1 : 10 000 to 1 : 50 had no effect on the contraction amplitude, but an enhanced effect has been found in a dilution range from 1 : 10 and 1 : 5. The presence of the endogenous activator of myocytes contractility (EAMC) has explained this enhanced effect. The β-adrenomodulation activity of blood serum has been explained by the presence of the endogenous sensitizer of β-AR (ESBAR) and the endogenous blocker of β-AR (EBBAR). The ESBAR activity of blood serum (dilutions: 1 : 1000, 1 : 500, 1 : 100, and 1 : 50) has been found in experiments with a subthreshold adrenaline concentration (10-8 g/ml). ESBAR (dilutions: 1 : 50 and 1 : 10) and EBBAR (dilution 1 : 500) activities of blood serum have been found in experiments with the maximum effective concentration of adrenaline (10-6 g/ml). Therefore, blood serum endogenous modulators of β-adrenergic reactivity, ESBAR and EBBAR, can modulate the activation of β-AR of human cardiomyocytes. These prove the prospects of the ESBAR analogue application in cardiology. © 2011 Pleiades Publishing, Ltd. Source

Razin M.P.,Kirov State Medical Academy | Zaitseva G.A.,Kirov Research Institute of Hematology and Blood Transfusion | Sukhikh N.K.,Kirov State Medical Academy
Medical News of North Caucasus

143 children of Russian ethnic group aged 5 - 15 years with various forms of congenital obstructive uropathy were observed. All patients underwent standard urological and immunogenetic examination to determine the factors of resistance to the development of pathology. In the study it was found that resistance to the development of congenital obstructive uropathies presents in individuals with HLA-alleles DRB1∗07, DRB1∗15 (2), DQB1∗0302; phenotypes A1, A9; A9, A11 and haplotype combinations A3, B7; A11, B35; A19, B27. Congenital resistance to the development of secondary pyelonephritis was in individuals with HLAantigens DRB1∗07, DRB1∗09, DRB1∗15 (2); phenotype A9, A11 and haplotype combinations A2, B12; A3, B7; A11, B35. Protective role in the development of congenital hydronephrosis in individuals was played by a specificities of HLA-system A11 and DQB1∗0302; phenotypic combinations A2, A9; A9, A11 and haplotypes A2, B7; A2, B12. Resistance to the presence of pyeloectasia (minor anomalies of the urinary tract) was in individuals with alleles HLA DRB1∗01, DRB1∗11 (5) and haplotype combination of antigens A3, B7. Source

Ikonnikova A.Y.,RAS Engelhardt Institute of Molecular Biology | Yatsenko Y.E.,RAS Engelhardt Institute of Molecular Biology | Kremenetskaya O.S.,Russian Academy of Sciences | Fesenko D.O.,RAS Engelhardt Institute of Molecular Biology | And 3 more authors.
Molecular Biology

A biochip-based method was developed to identify the BCR-ABL mutations that affect the thyrosine kinase domain and determine resistance to targeted therapy with thyrosine kinase inhibitors. The method is based on RT–PCR followed by allele-specific hybridization on a biochip with immobilized oligonucleotide probes. The biochip addresses 11 mutations, which are responsible for up to 85% of imatinib resistance cases. A method to decect the clinically significant mutation T315I was designed on the basis of LNA-clamped PCR and proved highly sensitive, detecting the mutation in clinical samples with a leukemic cell content of 5% or higher. The method was validated using clinical samples from chronic myeloid leukemia (CML) patients with acquired resistance to imatinib. The results of hybridization on biochip were verified by Sanger sequencing. © 2016, Pleiades Publishing, Inc. Source

Discover hidden collaborations